Nwam LLC Avidity Biosciences, Inc. Transaction History

Nwam LLC

$1.22 Billion
Q1 2024

A detailed history of Nwam LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Nwam LLC holds 27,362 shares of RNA stock, worth $1.16 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

27,362

Previous 29,321 6.68%

Holding current value

$1.16 Million

Previous $265,000 163.4%

% of portfolio

0.06%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$9.16 - $25.52 $17,944 - $49,993	-1,959 Reduced 6.68%	27,362 $698,000
Q4 2023 Feb 14, 2024	SELL	$4.87 - $9.37 $31,031 - $59,705	-6,372 Reduced 17.85%	29,321 $265,000
Q3 2023 Oct 31, 2023	BUY	$6.3 - $11.35 $31,046 - $55,932	4,928 Added 16.02%	35,693 $227,000
Q2 2023 Aug 09, 2023	BUY	$10.62 - $17.34 $98,394 - $160,655	9,265 Added 43.09%	30,765 $341,000
Q1 2023 May 12, 2023	BUY	$15.35 - $25.65 $57,700 - $96,418	3,759 Added 21.19%	21,500 $330,000

Q4 2022 Feb 07, 2023	SELL	$10.06 - $22.66 $20,120 - $45,320	-2,000 Reduced 10.13%	17,741 $393,000
Q1 2022 May 12, 2022	BUY	$14.2 - $23.78 $15,435 - $25,848	1,087 Added 5.83%	19,741 $365,000
Q4 2021 Feb 10, 2022	SELL	$20.4 - $28.66 $42,840 - $60,186	-2,100 Reduced 10.12%	18,654 $443,000
Q3 2021 Nov 03, 2021	SELL	$18.16 - $25.21 $34,504 - $47,899	-1,900 Reduced 8.39%	20,754 $511,000
Q2 2021 Aug 04, 2021	SELL	$19.62 - $29.26 $181,818 - $271,152	-9,267 Reduced 29.03%	22,654 $560,000
Q1 2021 Apr 23, 2021	BUY	$20.28 - $28.15 $647,357 - $898,576	31,921 New	31,921 $696,000

Others Institutions Holding RNA

# of Institutions

165

Shares Held

71.6M

Call Options Held

182K

Put Options Held

55K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $2.22B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.

Account